Cargando…

Altered Renal Vascular Responsiveness to Vasoactive Agents in Rats with Angiotensin II-Dependent Hypertension and Congestive Heart Failure

OBJECTIVE: We evaluated the hypothesis that the development of renal dysfunction and congestive heart failure (CHF) caused by volume overload in rats with angiotensin II (ANG II)-dependent hypertension is associated with altered renal vascular responsiveness to ANG II and to epoxyeicosatrienoic acid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vacková, Šárka, Kikerlová, Soňa, Melenovsky, Vojtěch, Kolář, František, Imig, John D., Kompanowska-Jezierska, Elzbieta, Sadowski, Janusz, Červenka, Luděk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107072/ https://www.ncbi.nlm.nih.gov/pubmed/31430751 http://dx.doi.org/10.1159/000501688

Ejemplares similares

Pharmacological Blockade of Soluble Epoxide Hydrolase Attenuates the Progression of Congestive Heart Failure Combined With Chronic Kidney Disease: Insights From Studies With Fawn-Hooded Hypertensive Rats
por: Vacková, Šárka, et al.
Publicado: (2019)

Deleterious Effects of Hyperactivity of the Renin-Angiotensin System and Hypertension on the Course of Chemotherapy-Induced Heart Failure after Doxorubicin Administration: A Study in Ren-2 Transgenic Rat
por: Kala, Petr, et al.
Publicado: (2020)

Kidney Response to Chemotherapy-Induced Heart Failure: mRNA Analysis in Normotensive and Ren-2 Transgenic Hypertensive Rats
por: Jíchová, Šárka, et al.
Publicado: (2021)

20-Hydroxyeicosatetraenoic acid antagonist attenuates the development of malignant hypertension and reverses it once established: a study in Cyp1a1-Ren-2 transgenic rats
por: Sedláková, Lenka, et al.
Publicado: (2018)

Early Renal Vasodilator and Hypotensive Action of Epoxyeicosatrienoic Acid Analog (EET-A) and 20-HETE Receptor Blocker (AAA) in Spontaneously Hypertensive Rats
por: Walkowska, Agnieszka, et al.
Publicado: (2021)

Impaired renal autoregulation and pressure-natriuresis: any role in the development of heart failure in normotensive and angiotensin II-dependent hypertensive rats?
por: Honetschlägerová, Zuzana, et al.
Publicado: (2023)

Effects of Epoxyeicosatrienoic Acid-Enhancing Therapy on the Course of Congestive Heart Failure in Angiotensin II-Dependent Rat Hypertension: From mRNA Analysis towards Functional In Vivo Evaluation
por: Kala, Petr, et al.
Publicado: (2021)

Addition of Endothelin A-Receptor Blockade Spoils the Beneficial Effect of Combined Renin-Angiotensin and Soluble Epoxide Hydrolase Inhibition: Studies on the Course of Chronic Kidney Disease in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats
por: Chábová, Věra Čertíková, et al.
Publicado: (2019)

Endothelin type A receptor blockade attenuates aorto-caval fistula-induced heart failure in rats with angiotensin II-dependent hypertension
por: Kala, Petr, et al.
Publicado: (2023)

Increased Endogenous Activity of the Renin-Angiotensin System Reduces Infarct Size in the Rats with Early Angiotensin II-dependent Hypertension which Survive the Acute Ischemia/Reperfusion Injury
por: Husková, Zuzana, et al.
Publicado: (2021)

Isovolumic loading of the failing heart by intraventricular placement of a spring expander attenuates cardiac atrophy after heterotopic heart transplantation
por: Pokorný, Martin, et al.
Publicado: (2018)

Epoxyeicosatrienoic Acid Analog and 20-HETE Antagonist Combination Prevent Hypertension Development in Spontaneously Hypertensive Rats
por: Baranowska, Iwona, et al.
Publicado: (2022)

The treatment with sGC stimulator improves survival of hypertensive rats in response to volume-overload induced by aorto-caval fistula
por: Gawrys, Olga, et al.
Publicado: (2023)

Inhibition of soluble epoxide hydrolase is renoprotective in 5/6 nephrectomized Ren-2 transgenic hypertensive rats
por: Kujal, Petr, et al.
Publicado: (2014)

Epoxyeicosatrienoic Acid-Based Therapy Attenuates the Progression of Postischemic Heart Failure in Normotensive Sprague-Dawley but Not in Hypertensive Ren-2 Transgenic Rats
por: Hrdlička, Jaroslav, et al.
Publicado: (2019)

High Salt Intake Increases Blood Pressure in Normal Rats: Putative Role of 20-HETE and No Evidence on Changes in Renal Vascular Reactivity
por: Walkowska, A., et al.
Publicado: (2015)

Renoprotection Provided by Additional Diuretic Treatment in Partially Nephrectomized Ren-2 Transgenic Rats Subjected to the Combined RAS and ET(A) Blockade
por: Vaněčková, Ivana, et al.
Publicado: (2019)

Inappropriate activation of the renin-angiotensin system improves cardiac tolerance to ischemia/reperfusion injury in rats with late angiotensin II-dependent hypertension
por: Husková, Zuzana, et al.
Publicado: (2023)

AT(1) receptor blocker, but not an ACE inhibitor, prevents kidneys from hypoperfusion during congestive heart failure in normotensive and hypertensive rats
por: Kratky, Vojtech, et al.
Publicado: (2021)

Effects of Trandolapril on Structural, Contractile and Electrophysiological Remodeling in Experimental Volume Overload Heart Failure
por: Jarkovská, Dagmar, et al.
Publicado: (2021)

Chymase Dependent Pathway of Angiotensin II Generation and Rapeseed Derived Peptides for Antihypertensive Treatment of Spontaneously Hypertensive Rats
por: Baranowska, Iwona, et al.
Publicado: (2021)

Proteomic and transcriptomic analysis of heart failure due to volume overload in a rat aorto-caval fistula model provides support for new potential therapeutic targets - monoamine oxidase A and transglutaminase 2
por: Petrak, Jiri, et al.
Publicado: (2011)

Effects of Renal Denervation on the Enhanced Renal Vascular Responsiveness to Angiotensin II in High-Output Heart Failure: Angiotensin II Receptor Binding Assessment and Functional Studies in Ren-2 Transgenic Hypertensive Rats
por: Honetschlägerová, Zuzana, et al.
Publicado: (2021)

Right versus left ventricular remodeling in heart failure due to chronic volume overload
por: Havlenova, Tereza, et al.
Publicado: (2021)

FGF-23 is a biomarker of RV dysfunction and congestion in patients with HFrEF
por: Benes, Jan, et al.
Publicado: (2023)

Nonselective and A2a-Selective Inhibition of Adenosine Receptors Modulates Renal Perfusion and Excretion Depending on the Duration of Streptozotocin-Induced Diabetes in Rats
por: Sitek, Joanna Dorota, et al.
Publicado: (2023)

Adrenomedullin: A vasoactive agent for sporadic and hereditary vascular cognitive impairment
por: Ihara, Masafumi, et al.
Publicado: (2021)

Angiotensin II, a unique vasoactive agent dissociates myosin light chain phosphorylation from contraction
por: HIRANO, Takashi, et al.
Publicado: (2017)

Endogenous Vasoactive Peptides and Vascular Aging-Related Diseases
por: Chen, Yao, et al.
Publicado: (2022)

Polyprenol-Based Lipofecting Agents for In Vivo Delivery of Therapeutic DNA to Treat Hypertensive Rats
por: Gawrys, Olga, et al.
Publicado: (2020)

The Effect of Chronic NO Synthase Inhibition on the Vasoactive and Structural Properties of Thoracic Aorta, NO Synthase Activity, and Oxidative Stress Biomarkers in Young SHR
por: Berenyiova, Andrea, et al.
Publicado: (2018)

Splanchnic Haemodynamics and Vasoactive Agents in Experimental Cirrhosis
por: Geraghty, J. G., et al.
Publicado: (1994)

Epinephrine: Is it really the black sheep of vasoactive agents?
por: Agrawal, Ritwick, et al.
Publicado: (2010)

Timing of vasoactive agents and corticosteroid initiation in septic shock
por: Ammar, Mahmoud A., et al.
Publicado: (2022)

Histamine, a vasoactive agent with vascular disrupting potential, improves tumour response by enhancing local drug delivery
por: Brunstein, F, et al.
Publicado: (2006)

Vascular Smooth Muscle Cell Stiffness and Adhesion to Collagen I Modified by Vasoactive Agonists
por: Hong, Zhongkui, et al.
Publicado: (2015)

Intermittent hypoxia regulates vasoactive molecules and alters insulin-signaling in vascular endothelial cells
por: Sharma, Pragya, et al.
Publicado: (2018)

Relationships between advanced glycation end products (AGEs), vasoactive substances, and vascular function
por: Matsumoto, Takayuki, et al.
Publicado: (2022)

Potentiation of the anti-tumour effect of melphalan by the vasoactive agent, hydralazine.
por: Stratford, I. J., et al.
Publicado: (1988)

Enhancement of chemotherapy and nitroimidazole-induced chemopotentiation by the vasoactive agent hydralazine.
por: Siemann, D. W.
Publicado: (1990)

Cannot write session to /tmp/vufind_sessions/sess_n8j3svohllld9dqor17guf7k3d